Valneva SE (VALN) Depreciation & Amortization - Total (2022 - 2026)
Valneva SE (VALN) posted Depreciation & Amortization - Total of $4.9 million for Q1 2026, down 1.76% sequentially from $5.0 million in Q4 2025, and up 11.3% YoY from $4.4 million in Q1 2025.
Valneva SE (VALN) Depreciation & Amortization - Total (2022 - 2026) Analysis & Trends
Valneva SE has reported Depreciation & Amortization - Total for 5 years, with the latest figure at $4.9 million in Q1 2026.
- Quarterly Depreciation & Amortization - Total rose 11.3% year-over-year to $4.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $19.6 million (up 18.53% YoY) and the FY2025 annual result came in at $19.7 million, up 23.64% from the prior year.
- Depreciation & Amortization - Total eased to $4.9 million in Q1 2026 per VALN's latest filing, from $5.0 million in the prior quarter.
- Over five years, Depreciation & Amortization - Total peaked at $10.7 billion in Q3 2022 and troughed at -$10.8 billion in Q4 2022.
- A 5-year average of -$4.5 million and a median of $4.1 million in 2024 frame the typical range for Depreciation & Amortization - Total.
- The widest YoY moves for Depreciation & Amortization - Total: up 100.03% in 2023, down 99.97% in 2023.
- Over 5 years, Depreciation & Amortization - Total stood at -$10.8 billion in 2022, then soared by 100.03% to $3.7 million in 2023, then advanced by 16.84% to $4.3 million in 2024, then increased by 17.1% to $5.0 million in 2025, then fell by 1.76% to $4.9 million in 2026.
- According to Business Quant data, Depreciation & Amortization - Total over the past three periods registered $4.9 million, $5.0 million, and $4.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Dep. & Amort. (Tot) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Valneva SE | 618.67 Mn | 477.41 Mn | 1.86 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.92 Mn |
| Dec 31, 2025 | 5.01 Mn |
| Sep 30, 2025 | 4.91 Mn |
| Jun 30, 2025 | 4.75 Mn |
| Mar 31, 2025 | 4.42 Mn |
| Dec 31, 2024 | 4.27 Mn |
| Sep 30, 2024 | 4.06 Mn |
| Jun 30, 2024 | 3.77 Mn |
| Mar 31, 2024 | 3.80 Mn |
| Dec 31, 2023 | 3.66 Mn |
| Sep 30, 2023 | 3.27 Mn |
| Jun 30, 2023 | 3.05 Mn |
| Mar 31, 2023 | 2.79 Mn |
| Dec 31, 2022 | -10.78 Bn |
| Sep 30, 2022 | 10.66 Bn |